MolMed
 |
|
| Public | |
| Traded as | BIT: MLM |
| Industry | Biotechnology |
| Founded | 1996 |
| Headquarters | Milan, Italy |
|
Key people
|
Claudio Bordignon (Chairman) and CEO) |
| Products | TK cell therapy, NGR-hTNF (antitumor recombinant protein) |
| Revenue | € 6.714 2013 |
 € 18.169 2013 |
|
|
Number of employees
|
120 2013 |
| Website | www |
MOLMED is a medical biotechnology company located in Milan, inside the San Raffaele Biomedical Science Park(which houses the San Raffaele research hospital and Scientific Institute, and a private university). The company was founded by Claudio Bordignon in 1996 as a joint venture between Science Park Raf and Boehringer Mannheim, in order to create a cGMP structure specialised in the ex vivo manipulation of human cells for supplying gene and cell therapy services for clinical trial protocols.
MolMed activities cover all functions, from discovery to proof of clinical activity, focuses on oncology indications that require new therapy options and has an in-house GMP-based manufacturing of cell and gene therapy products.
MolMed's product portfolio contains two therapeutic antitumour drugs undergoing clinical trial: TK cell therapy product that permits bone marrow transplant from donors that are partially compatible with the patient, in Phase III for the treatment of high-risk leukaemia;NGR-hTNF (antitumor recombinant protein), a recombinant biological drug that targets tumour blood vessels, in Phase III in malignant pleural mesothelioma and in Phase II in six other indications: colorectal, liver and ovarian cancers, small-cell lung cancer, non-small cell lung cancer and in soft-tissue sarcomas.
MolMed also provides high-level competencies in gene and cell therapy for the development, performance and validation of projects for third parties; said competencies range from preclinical studies to Phase III clinical trials, including the production in compliance with current GMP of viral vectors and patient-specific genetically modified cells for clinical use.
MolMed was founded in 1996 as a joint venture between Science Park Raf and Boehringer Mannheim, with the objective of creating a cutting-edge cGMP structure, specialized in the ex vivo manipulation of human cells for the supply of gene therapy services for clinical trial protocols.
In the course of the first three years, Boehringer Mannheim was acquired by Roche which then sold its equity stake in MolMed to the EDCP venture capital fund.
In 2000, MolMed's corporate model changed the service company into a biopharmaceutical product company, and the company developed further, adding the operations typical of a biopharmaceutical development company to its service business, with a focus on new therapies for the cure of cancer.
...
Wikipedia